Search

Nov 22, 2024
London Healthcare Week: The CEO of Arbutus summarizes IM-PROVE I phase 2a data for imdusiran in chronic hepatitis B presented earlier this week at The Liver Meeting
Michael McElhaugh describes how 25% of patients overall, and 50% of patients who had low baseline levels of hepatitis B surface antigen,...

Jun 20, 2024
The CEO of Arbutus (interim) describes the company's work in hepatitis B and highlights recent EASL data
Michael McElhaugh describes data presented at EASL for the RNAi therapeutics imdusiran, explains the rationale for the PD-L1, and more.